Publisher： Bentham Science Publishers
E-ISSN： 2212-4071|7|2|141-156
ISSN： 1574-891X
Source： Recent Patents on Anti-Infective Drug Discovery, Vol.7, Iss.2, 2012-08, pp. : 141-156
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
A number of recent studies revealed that successful treatment of the patients with MDR/XDR- TB was not achieved due to high resistant rates to many second-line drugs such as kanamycin and prothionamide including poor adherence of the lengthy treatment. Many new drugs and compounds such as benzothiazinones, meropenem, PA-824, isoflavonoids, rhein, PNU-100480, TMC207, SQ109, OPC-67683, AZD5847, and linezolid are currently in development pipeline. According to very few patents in new compounds and drugs against MDR/XDRMycobacterium tuberculosis bacilli have been currently introduced, so inventors must be encouraged to contribute to this area worldwide.
Related content
By Gonzalo Ximena Drobniewski Francis
Journal of Antimicrobial Chemotherapy, Vol. 68, Iss. 2, 2013-02 ,pp. :
Access to resources
Recommend
Recent Patents on Anti-Infective Drug Discovery, Vol. 8, Iss. 3, 2013-01 ,pp. :
Multi-Drug Resistant Pulmonary Tuberculosis
Current Respiratory Medicine Reviews, Vol. 2, Iss. 1, 2006-02 ,pp. :
Recent Patents on Anti-Infective Drug Discovery, Vol. 6, Iss. 2, 2011-05 ,pp. :